euro cryptocurrency- Top Reviews

After the market closed, the Shanghai Municipal Government issued the Action Plan for Shanghai to Support the Merger and Reorganization of Listed Companies (2025-2027). Among them, it is proposed to strive to land a number of representative M&A cases in key industries by 2027, and cultivate about 10 internationally competitive listed companies in key industries such as integrated circuits, biomedicine and new materials, forming a scale of M&A transactions of 300 billion yuan and activating total assets of over 2 trillion yuan. In addition, the plan also mentioned that the merger of securities companies should be accelerated to build a first-class investment bank.In addition, it is planned to distribute a cash dividend of 12.3 yuan to all shareholders for every 10 shares, with a total dividend of 4.5 billion yuan. In April this year, Ningde has paid dividends of 22 billion yuan, and this time it totaled 27.4 billion yuan. According to the current market value of 11,900, the corresponding dividend yield is 2.3%! It's really not low.True Vision: The controlling shareholder and others intend to reduce their holdings by 4% in total;

Recently, all localities are vigorously promoting mergers and acquisitions, first in Shenzhen and then in Shanghai, and it is estimated that Beijing will soon. The listed companies in the north and Shenzhen are all active, and the merger of Shanghai benchmark brokerage Haitong+Guotai Junan has landed! Other places will follow suit, but mergers and acquisitions are really difficult to grasp, and it is estimated that there are more local+state-owned assets.Guoxin Technology: shareholders such as the National Fund intend to reduce their holdings by no more than 3%;

Second, Contemporary Amperex Technology Co., Limited's enlargement trick: special dividends for factories in EuropeAmong them, the biggest benefit is the biomedical industry. It is necessary to set up a M&A fund with a scale of 10 billion, which is specifically aimed at the merger and reorganization of the biomedical industry! The focus is on local enterprises in Shanghai, especially the biomedicine of listed companies in Shanghai.First, heavy! Shanghai merger and reorganization action plan announced